ODM-207 (ODM207) is a highly potent, selective and orally active pan-BET inhibitor with potent and broad antiproliferative effects.
ODM-207 effectively inhibits the proliferation of ER+ breast cancer cell lines by inducing cell cycle arrest in G0/G1-phase.
ODM-207 suppresses the growth of ER+ patient-derived breast cancer xenograft tumors. ODM-207 was shown to synergize with palbociclib in vitro in ER+ breast cancer cell lines.
ODM-207 targeted several pathways important for cancer progression such as MYC, estrogen response and cell cycle gene signatures.
The combination of ODM-207 and CDK4/6 inhibitor palbociclib achieved greater cell proliferation inhibition than either drug alone at sub IC50 concentrations.
